Physician profile

Phyllis Emma

Psychiatric/Mental Health (Nurse Practitioner) · Brooklyn, NY

NPI 1598805319

$577.58

in general payments reported to CMS, 2019-2025

10 companies · $13.77 in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$71.84

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $194.38 2021-2025
Janssen Pharmaceuticals, INC $58.86 2021
Eisai INC. $57.92 2021
Takeda Pharmaceuticals U.S.A., INC. $55.76 2021
Vanda Pharmaceuticals INC. $55.08 2021
Bausch Health US, LLC $51.73 2021
Lundbeck LLC $36.99 2021
Adlon Therapeutics L.P. $28.06 2021
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $19.82 2021
Otsuka America Pharmaceutical, INC. $18.98 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Phyllis Emma

$577.58

in general payments reported 2019-2025

Years
2021-2025
Top company
Abbvie INC.

https://glasscript.com/doctor/10552108/phyllis-emma

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.